EPS for Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Expected At $-1.49

July 14, 2018 - By Richard Slagle

Analysts expect Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) to report $-1.49 EPS on August, 13.They anticipate $0.29 EPS change or 16.29 % from last quarter’s $-1.78 EPS. After having $-2.32 EPS previously, Biohaven Pharmaceutical Holding Company Ltd.’s analysts see -35.78 % EPS growth. The stock increased 0.36% or $0.15 during the last trading session, reaching $41.8. About 212,171 shares traded. Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) has risen 50.20% since July 14, 2017 and is uptrending. It has outperformed by 37.63% the S&P500.

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops product candidates to treat neurological diseases, including rare disorders. The company has market cap of $1.67 billion. The Company’s advanced product candidate includes rimegepant, which is intended to initiate two Phase III clinical trials for the acute treatment of migraine; and trigriluzole, which is in a Phase II/III clinical trial used for the treatment of ataxias with an initial focus on spinocerebellar ataxia. It currently has negative earnings. The firm also develops BHV-3500 for the prevention of chronic and episodic migraine; BHV-0223 for the treatment of amyotrophic lateral sclerosis, a neurodegenerative disease that affects nerve cells in the brain and spinal cord; and BHV-5000 for the treatment of symptoms associated with Rett syndrome, such as breathing irregularities.

More recent Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) news were published by: Streetinsider.com which released: “Biohaven Pharmaceutical Holding (BHVN) PT Raised to $48 at Needham & Company; Adding Migraine Prevention …” on July 02, 2018. Also Benzinga.com published the news titled: “Benzinga’s Daily Biotech Pulse: Sarepta’s DMD Gene Therapy, Anika’s Flunked Trial, Eidos To Commence Trading” on June 20, 2018. Seekingalpha.com‘s news article titled: “Biohaven and Royalty Pharma announce royalty funding and stock purchase agreements totaling $150M” with publication date: June 19, 2018 was also an interesting one.

Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.